Alnylam Pharmaceuticals stock price target raised by Raymond James on strong Amvuttra sales
PositiveFinancial Markets

Alnylam Pharmaceuticals has received a boost as Raymond James raised its stock price target, citing strong sales of its drug Amvuttra. This is significant because it reflects investor confidence in Alnylam's growth potential and the effectiveness of Amvuttra in treating patients, which could lead to increased market interest and investment in the company.
— Curated by the World Pulse Now AI Editorial System








